Development Of Cancer Immunotherapy Using Gene-engineered T Cells In A Self-antigen Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$428,602.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells.
Mechanisms Of Action Of The Antigen Presenting Cells That Impair Lymphoma-specific Cytotoxic T Lymphocytes
Funder
National Health and Medical Research Council
Funding Amount
$295,983.00
Summary
Our immune systems are continually fighting cancer. However, the cancer cells occasionally acquire mutations that enable them to subvert the immune system. Usually they do this by hiding under the appearance of normal tissue, but sometimes they activate the very mechanisms that are in place to shut-down immune responses when these are no longer necessary. The goal of this proposal is to identify such mechanisms and find ways of bypassing them, thus restoring anti-tumour activity in patients.